1I
1I4.F HeraMED Limited
- Market cap
- EUR 23.8M
- P/E
- -
- P/B
- 15.23x
- ROE
- -443.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 1I4.F undervalued?
Graham numberThe Graham number of HeraMED Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HeraMED Limited fundamental analysis
No fundamental analysis for HeraMED Limited yet.
HeraMED Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HeraMED Limited
HeraMED Limited, a medical data and technology company, develops, manufactures, and sells home-based maternity monitoring technology in Australia and the United States. It provides HeraBEAT, a medical device for fetal and maternal heart rate used by pregnant women; and HeraCARE, a digital maternity and women's health platform that focuses on improving clinical outcomes while supporting more efficient and accessible models of care. The company has a collaboration agreement wi…
Full company profileHeraMED Limited financial statements
HeraMED Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | 109K | 208K | 51.3K | 86.7K | 322K | 591K | 364K | 293K |
| Gross Profit | - | - | -80.6K | 48.3K | 10.3K | 44.4K | 207K | 355K | 219K | 293K |
| Operating Income | - | - | -4.07M | -4.61M | -4.48M | -3.94M | -4.68M | -6.51M | -5.57M | -3.60M |
| EBITDA | - | - | -3.78M | -4.11M | -4.01M | -3.76M | -4.09M | -5.83M | -5.12M | -3.98M |
| Net Income | - | - | -5.34M | -4.47M | -4.36M | -5.71M | -7.17M | -6.61M | -5.49M | -4.13M |
| EPS | - | - | -0.06 | -0.04 | -0.03 | -0.03 | -0.03 | -0.02 | -0.01 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | - | - | 7.83M | 5.14M | 4.15M | 4.59M | 6.11M | 2.79M | 4.48M | 1.49M |
| Total Liabilities | - | - | 1.68M | 1.74M | 1.55M | 4.70M | 1.90M | 2.71M | 1.71M | 560K |
| Shareholders' Equity | - | - | 6.15M | 3.41M | 2.59M | -106K | 4.21M | 685K | 2.77M | 931K |
| Cash & Short-term Investments | - | - | 5.72M | 2.92M | 2.47M | 3.56M | 3.85M | 1.06M | 3.13M | 1.37M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.43M | -547K | -1.77M | -2.65M | -2.78M | -3.23M | - | - | - | - |
| Capital Expenditure | 0.00 | 2.25K | 5.05K | 6.48K | 4.68K | 18.8K | 1.02M | 2.05K | 0.00 | 0.00 |
| Free Cash Flow | - | - | -2.51M | -3.90M | -3.63M | -3.32M | -4.78M | -5.57M | -4.81M | -3.66M |
| Ratios | ||||||||||
| ROE | - | - | -86.8% | -131.0% | -168.1% | - | -170.6% | -964.8% | -198.1% | -443.8% |
| ROA | - | - | -68.2% | -86.8% | -105.2% | -124.4% | -117.4% | -236.7% | -122.4% | -277.1% |
| Net Profit Margin | - | - | -4,880.8% | -2,152.1% | -8,500.3% | -6,588.2% | -2,229.5% | -1,117.6% | -1,507.0% | -1,408.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
HeraMED Limited dividends
HeraMED Limited has not paid dividends in the last 10 fiscal years.
Who owns HeraMED Limited
- Insiders 30.75%
- Institutions 2.97%
- Public & others 66.28%
- Shares outstanding 1.16B
- Free float 816M
HeraMED Limited company profile
- Company name
- HeraMED Limited
- Ticker
- 1I4.F
- ISIN
- AU0000028367
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- 117 Camberwell Road, Hawthorn East, VIC, Australia, 3123
- Phone
- 61 2 7251 1888
- Website
- hera-med.com
About HeraMED Limited
HeraMED Limited, a medical data and technology company, develops, manufactures, and sells home-based maternity monitoring technology in Australia and the United States. It provides HeraBEAT, a medical device for fetal and maternal heart rate used by pregnant women; and HeraCARE, a digital maternity and women's health platform that focuses on improving clinical outcomes while supporting more efficient and accessible models of care. The company has a collaboration agreement with Mayo Clinic. HeraMED Limited was founded in 2011 and is based in Hawthorn East, Australia.
HeraMED Limited management
8- Ms. Anoushka GungadinMD, CEO & Director
- Mr. Cameron Peter Jones C.A.CFO & Joint Company Secretary
- Mr. Vivek KrishnanChief Technology Officer
- Henry JordanHead of Investor Relations
- Dr. Mandy KhairaChief Clinical Transformation Officer & Chief Medical Officer
- Ms. Nicole ZappalaHead of Customer Success
- Mr. Jeff GaribaldiChief Growth Officer
- Ms. Nova Anne TaylorJoint Company Secretary